AOTMiT: The Transparency Council will evaluate drugs in diabetology, cardiology and oncology, among others

The agenda includes:

1. Preparation of a position paper on the evaluation of the drug Forxiga (dapagliflozinum) for the indication: type 2 diabetes.
2. Preparation of a position paper on the evaluation of the drug Verzenios (abemaciclibum) under the drug program B.9.FM. "Treatment of patients with breast cancer (ICD-10: C50)".
3. Preparation of a position paper on the evaluation of the drug HyQvia (immunoglobulinum humanum normale) under drug program B.67. "Immunoglobulin treatment of neurological diseases (ICD-10: G61.8, G62.8, G63.1, G70, G04.8, G73.1, G73.2, G72.4, G61.0, G36.0, G25.82, M33.0, M33.1, M33.2)".
4. Preparation of a position paper on the evaluation of the drug Nucala (mepolizumab) within the framework of the drug program "Treatment of patients with hypereosinophilic syndrome (HES) (ICD-10: D72.11)".
5. Preparation of a position paper on examining the appropriateness of issuing reimbursement approvals for the medicinal product Rythmodan (disopyramide) for the indications:

1) supraventricular arrhythmias (atrial fibrillation, atrial flutter, atrial tachycardia, atrial premature excitation),

2) ventricular arrhythmias (premature ventricular beats, ventricular tachycardia, ventricular fibrillation and flutter),

3) Hypertrophic cardiomyopathy with left ventricular outflow tract narrowing.

6 Prepare an opinion on the draft health policy program of the local government unit "Program of prevention of stress-related diseases in working people in the territory of the Małopolska province".

Source: AOTMiT